- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04169776
Effect of Daily Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) on Proteinuria in Pediatric Patients With Idiopathic Nephrotic Syndrome (taVNS)
Effect of Daily Transcutaneous Auricular Vagus Nerve (taVNS) Stimulation on Proteinuria in Pediatric Patients With Idiopathic Nephrotic Syndrome
Study Overview
Status
Intervention / Treatment
Detailed Description
Idiopathic nephrotic syndrome is defined as the development of proteinuria, edema, hypoalbuminemia, and hyperlipidemia often presenting in the pediatric population. The underlying pathogenesis of idiopathic nephrotic syndrome is poorly understood but likely involves dysregulation of the immune system, and the majority of patients respond to steroid therapy and other immunosuppressive therapy. Unfortunately, relapses are common, with at least one relapse occurring in up to 90% of patients. Frequently-relapsing patients may be exposed large amounts of steroids and other immunosuppressants with a multitude of adverse effects, while others may not even respond to these treatments. Therefore, novel therapies are being studied.
Vagus nerve stimulation is a novel therapy with the potential to treat inflammatory conditions via inhibition of cytokine release by the cholinergic anti-inflammatory pathway. The purpose of the proposed study is to investigate the use of vagus nerve stimulation in the prevention of nephrotic syndrome relapses and treatment of proteinuria in pediatric patients with idiopathic nephrotic syndrome.
Patients will be enrolled if they have frequently-relapsing idiopathic nephrotic syndrome or proteinuria which does not respond to steroid therapy. These patients will perform daily transcutaneous auricular Vagus Nerve stimulation (taVNS) therapy 5 minutes a day for a 6 month period and will be monitored for urine/bloodwork or clinical signs of nephrotic syndrome relapse.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
New York
-
New Hyde Park, New York, United States, 11040
- Northwell
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria (Arm 1):
- Subjects age 2-21 years of age
- eGFR > 60 ml/min/1.73 m2
- Diagnosis of idiopathic minimal change disease (clinical diagnosis or per biopsy)
- Prior history of remission of nephrotic syndrome within 4 weeks of initiation of steroid therapy (steroid sensitive nephrotic syndrome)
- 2 or more episodes of nephrotic syndrome relapses in a 6-month period or four or more episodes of nephrotic syndrome relapses in a 12-month period (relapse defined as 2+ proteinuria on first morning urine sample for three consecutive days or development of edema)
- In remission (no proteinuria - normal urine protein to creatinine ratio < 0.2) at the time of enrollment
Inclusion Criteria (Arm 2):
- Subjects age 2-21 years of age
- eGFR > 60 ml/min/1.73 m2
- Diagnosis idiopathic nephrotic syndrome (clinical diagnosis or per biopsy)
- Diagnosis of steroid-resistant nephrotic syndrome (symptoms or proteinuria not improved after 4 to 8 weeks of steroid therapy)
- Persistent proteinuria (first-morning urine protein to creatinine ratio > 0.2)
- At least 7 days since last dose of steroids
Exclusion Criteria (Arm 1):
- Subjects with nephrotic syndrome etiology other than idiopathic minimal change disease either biopsy-proven or by genetic testing
- Nephrotic syndrome due to secondary causes such as SLE, vasculitis, hepatitis, post-infectious etiology, medication-induced, etc.
- Subjects that did not achieve remission of nephrotic syndrome within 4 weeks of initiation of steroid therapy (steroid-resistant nephrotic syndrome)
- Subjects with urine protein to creatinine ratio of > 0.2 (not in remission)
- Subjects currently receiving any standing immunosuppressive therapy (mycophenolate mofetil, tacrolimus, rituximab - note: 1) previous exposure to these therapies does not exclude participation; 2) subjects with previous exposure to rituximab are eligible if B cells are replete)
- Subjects with a history of cardiac issues, including bradycardia, arrhythmias or structural abnormalities of the heart
- Subjects with implantable electronic devices such as pacemakers, defibrillators, hearing aids, cochlear implants or deep brain stimulators
- Subjects with any other known inflammatory condition (IBD, SLE, etc.)
Exclusion Criteria (Arm 2):
- Nephrotic syndrome due to secondary causes such as SLE, vasculitis, hepatitis, post-infectious etiology, medication-induced, etc.
- Subjects with a history of cardiac issues, including bradycardia, arrhythmias or structural abnormalities of the heart
- Subjects with implantable electronic devices such as pacemakers, defibrillators, hearing aids, cochlear implants or deep brain stimulators
- Subjects with any other known inflammatory condition (IBD, SLE, etc.)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: DEVICE_FEASIBILITY
- Allocation: NON_RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Steroid Sensitive Frequently-Relapsing Nephrotic Syndrome
Individuals in this arm of the study will have to have a diagnosis of steroid sensitive frequently relapsing idiopathic nephrotic syndrome.
They will receive transcutaneous auricular VNS (taVNS) performed for 5minutes every day for 6 months.
The settings of the taVNS device will be individualized for each patient.
Data will be collected on the the number of nephrotic syndrome relapses, the time between relapses, the time to remission once relapsed, and the level of proteinuria before and while using taVNS therapy.
|
Participants in this study will perform home transcutaneous auricular vagus nerve stimulation (taVNS) for 5 minutes a day for a 6-month period.
The device that will be used is the commercially available Roscoe Medical TENS 7000 vagus nerve stimulator.
The device will be attached to the Cymba Concha of the ear via an electrode ear clip.
The intensity of the stimulation will be slowly increased and adjusted to individual tolerability for each treatment.
TaVNS will be performed for 5 minutes daily for a period of 6 months.
|
EXPERIMENTAL: Steroid Resistant Idiopathic Nephrotic Syndrome
Individuals in this arm of the study will have to have a diagnosis of steroid resistant idiopathic nephrotic syndrome.
They will receive transcutaneous auricular VNS (taVNS) performed for 5minutes every day for 6 months.
The settings of the taVNS device will be individualized for each patient.
Data will be collected on the the number of nephrotic syndrome relapses, the time between relapses, the time to remission once relapsed, and level of proteinuria before and while using taVNS therapy.
|
Participants in this study will perform home transcutaneous auricular vagus nerve stimulation (taVNS) for 5 minutes a day for a 6-month period.
The device that will be used is the commercially available Roscoe Medical TENS 7000 vagus nerve stimulator.
The device will be attached to the Cymba Concha of the ear via an electrode ear clip.
The intensity of the stimulation will be slowly increased and adjusted to individual tolerability for each treatment.
TaVNS will be performed for 5 minutes daily for a period of 6 months.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety and tolerability of taVNS (Arms 1 and 2)
Time Frame: 6 months
|
The endpoint of heart rate monitoring as a measure of safety of taVNS in this population was selected as this is the most concerning adverse effect of taVNS therapy. If there is no heart rate-related events during this study, it would further justify safe use of taVNS in the pediatric population. Tolerability is an important measure in this study but is mostly a subjective measure. Therefore, patients who withdraw due to intolerability or report side effects which are deemed intolerable will aid in determining the feasibility of taVNS use in this population. |
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Impact of taVNS on cytokine levels (Arms 1 and 2)
Time Frame: 6 months
|
TaVNS has been shown in literature to have an anti-inflammatory effect when stimulating the vagus nerve.
Several studies have found that cytokine levels are increased in nephrotic syndrome relapses as compared to levels when in remission.
This endpoint provides a measure of the efficacy and compliance of taVNS use while also providing a marker for the effect of taVNS on the patient.
Finally, if taVNS is shown to reduce the number of relapses while also suppressing cytokine levels, it may suggest a cytokine-associated etiology of idiopathic nephrotic syndrome.
|
6 months
|
Impact of taVNS on number of nephrotic syndrome relapses, time to nephrotic syndrome relapses, and time to remission (Arm 1)
Time Frame: 6 months
|
This outcome was chosen as an important measure of the efficacy of taVNS on patients with idiopathic nephrotic syndrome.
A reduction in the number of relapses suggests that taVNS is a potential therapy for idiopathic nephrotic syndrome.
|
6 months
|
Impact of taVNS on level of proteinuria (Arm 2)
Time Frame: 6 months
|
The marker of disease progression and worsening outcomes is the level of proteinuria in patients with steroid-resistant idiopathic nephrotic syndrome.
Measurement of the urine protein to creatinine level on a first morning sample is the most feasible and accurate measure of proteinuria in this patient population.
|
6 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Christine Sethna, MD, Northwell Health
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 19-0861
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- ICF
- ANALYTIC_CODE
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Idiopathic Nephrotic Syndrome
-
University Hospital, LimogesHoffmann-La RocheCompletedChildhood Idiopathic Nephrotic SyndromeFrance, Belgium
-
University of CalgaryUnknownNephrotic Syndrome in Children | Nephrotic Syndrome, Minimal Change | Nephrotic Syndrome,IdiopathicCanada
-
Hoffmann-La RocheRecruitingChildhood Idiopathic Nephrotic SyndromeBelgium, United States, Poland, China, France, Spain, Japan, Brazil, Italy, Turkey
-
Nanjing University School of MedicineCompletedGlucocorticoid in Treatment of Adult Idiopathic Nephrotic Syndrome:a Prospective Observational StudyNephrotic Syndrome,IdiopathicChina
-
Istituto Giannina GasliniCompleted
-
Fondazione IRCCS Ca' Granda, Ospedale Maggiore...Cell Factory Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico; Laboratorio...CompletedIdiopathic Nephrotic Syndrome | Nephrotic Syndrome in Children | Steroid-Dependent Nephrotic SyndromeItaly
-
Assistance Publique - Hôpitaux de ParisCompletedIdiopathic Nephrotic SyndromeFrance
-
National and Kapodistrian University of AthensUnknownIdiopathic Nephrotic SyndromeGreece
-
Assistance Publique - Hôpitaux de ParisCompletedIdiopathic Nephrotic SyndromeFrance
-
Emory UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)RecruitingIdiopathic Nephrotic SyndromeUnited States
Clinical Trials on Transcutaneous Auricular Vagus Nerve (taVNS) stimulation
-
Guang'anmen Hospital of China Academy of Chinese...China Association for Science and TechnologyRecruiting
-
Sahlgrenska University Hospital, SwedenRecruitingBorderline Personality DisorderSweden
-
Burrell College of Osteopathic MedicineRecruitingPsoriasis VulgarisUnited States
-
Medical University of South CarolinaEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedVagus Nerve Stimulation | Infant Development | Poor FeedingUnited States
-
Medical University of South CarolinaEunice Kennedy Shriver National Institute of Child Health and Human Development...RecruitingInfant Feeding Problems, taVNSUnited States
-
Burrell College of Osteopathic MedicineCompletedObesity | Diabetes Mellitus, Type 2United States
-
Medical University of South CarolinaNational Institutes of Health (NIH)Active, not recruitingStroke | Stroke Sequelae | Motor ActivityUnited States
-
University of HartfordNot yet recruitingHealthy VolunteersUnited States
-
Medical University of South CarolinaNational Institutes of Health (NIH); National Institute of General Medical...Completed
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityRecruitingNeuropathic Pain | Radiotherapy Side EffectChina